Taro Pharmaceutical Indus (TARO.US): The 2024 Q4 financial report achieved revenue of US$164.9 million, previous value of US$146.6 million; earnings per share of $0.43, previous value of $0.18.
Taro Pharmaceutical Indus(TARO.US)：2024年Q4财报实现营收1.649亿美元，前值为1.466亿美元；每股收益为0.43美元，前值为0.18美元。
Taro Pharmaceutical Indus (TARO.US): The 2024 Q4 financial report achieved revenue of US$164.9 million, previous value of US$146.6 million; earnings per share of $0.43, previous value of $0.18.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.